

Evidence of New Intragenic HBB Haplotypes Model for the Prediction of Beta-Thalassemia in the Malaysian Population

Nur-Aisyah Aziz

Universiti Sultan Zainal Abidin

Wan-Rohani Wan Taib (✉ wanrohani@unisza.edu.my)

Universiti Sultan Zainal Abidin

Nur-Khairunnisa Kharolazaman

Universiti Sultan Zainal Abidin

Imilia Ismail

Universiti Sultan Zainal Abidin

Hamid Ali Nagi Al-Jamal

Universiti Sultan Zainal Abidin

Wan-Arfah Nadiah Wan Abdul Jamil

Universiti Sultan Zainal Abidin

Ezalia Esa

Institute for Medical Research (IMR), National Institute for Health Malaysia

Hishamshah Ibrahim

Malaysia Thalassemia Registry, Medical Development Division, Ministry of Health (MOH)

Research Article

Keywords: Beta-thalassemia, HBB gene, haplotype, SNP, Malaysia

Posted Date: March 22nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-313477/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on August 18th, 2021.
See the published version at <https://doi.org/10.1038/s41598-021-96018-y>.

1 **Evidence of new intragenic *HBB* haplotypes model for the prediction of beta-**
2 **thalassemia in the Malaysian population**

3

4 ^{1,2}Nur-Aisyah Aziz, ¹Wan-Rohani Wan Taib, ¹Nur-Khairunnisa Kharolazaman, ¹Imilia
5 Ismail, ¹Hamid Ali Nagi Al-Jamal, ¹Wan-Arfah Nadiah Wan Abdul Jamil, ²Ezalia Esa,
6 ³Hishamshah Ibrahim.

7 ¹Faculty of Health Sciences, Universiti Sultan Zainal Abidin, Gong Badak Campus,
8 Terengganu Malaysia.

9 ²Molecular Genetics Laboratory, Haematology Unit, Cancer Research Centre,
10 Institute for Medical Research (IMR), National Institute of Health (NIH), Ministry of
11 Health Malaysia.

12 ³Malaysian Thalassemia Registry, Medical Development Division, Ministry of Health
13 (MOH).

14

15 Corresponding author: Wan Rohani Wan Taib, Faculty of Health Sciences, Universiti
16 Sultan Zainal Abidin, Gong Badak Campus, Terengganu, Malaysia. Email:
17 wanrohani@unisza.edu.my

18

19 **ABSTRACT**

20

21 This study sought to determine the potential role of *HBB* haplotypes for the prediction
22 of beta-thalassemia in the Malaysian population. A total of 543 archived samples were
23 reviewed and selected for this study. Five tagging SNPs in the beta-globin gene (*HBB*;
24 NG_000007.3) were recorded and analysed for SNP-based and haplotype association
25 using SHEsis online software. Single-SNP-based association analysis showed three
26 tagging SNPs have statistical significant association with beta-thalassemia; IVS2-
27 16G>C ($p=0.036$), IVS2-666C>T ($p=0.032$) and 3'UTR +314G>A ($p=0.004$). However,
28 two tagging SNPs assigned as IVS2-74T>G and 3'UTR +233G>C did not yield
29 significant association with p -value 0.099 and 0.211, respectively. In a further
30 investigation, combined five tagging SNPs for haplotype association analysis revealed
31 three susceptible haplotypes with significant p -values of which, assigned as
32 haplotypes 1-2-2-1-1 ($p=6.49 \times 10^{-7}$, OR=10.371 [3.345~32.148]), 1-2-1-1-1 ($p=0.009$,
33 OR=1.423 [1.095~1.850]) and 1-1-1-1-1 ($p=1.39 \times 10^{-4}$, OR=10.221 [2.345~44.555]).
34 Another three haplotypes were found to be protective haplotype with significant p -
35 value of which assigned as haplotypes 2-2-1-1-1 ($p=0.006$, OR=0.668 [0.500~0.893]),
36 1-1-2-2-1 ($p=0.013$, OR=0.357 [0.153~0.830]) and 1-1-2-1-1 ($p=0.033$, OR=0.745
37 [0.567~0.977]). This study has identified the potential use of intragenic polymorphic
38 markers in the *HBB* gene, which were significantly associated with beta-thalassemia.
39 A combination of these five tagging SNPs defined a new haplotype model for beta-
40 thalassemia and further evaluation for the prediction of severity in beta-thalassemia.

41

42 Keyword: Beta-thalassemia, *HBB* gene, haplotype, SNP, Malaysia

43

44 1. INTRODUCTION

45

46 Haemoglobin disorders are the most common monogenic disease worldwide^{1,2}. These
47 inherited autosomal recessive disorders are classified according to the haemoglobin
48 expression or synthesis. There are three main categories of haemoglobin disorders;
49 haemoglobinopathy is the structurally abnormal haemoglobin, thalassemia is the
50 quantitatively reduced haemoglobin^{3,4} and, hereditary persistence of foetal
51 haemoglobin (HPFH) and $\delta\beta$ -thalassemia are characterized by increased levels of
52 foetal haemoglobin (HbF) in adulthood. The prevalence of haemoglobin disorders was
53 high in tropical and subtropical regions such as sub-Saharan Africa, Mediterranean,
54 Middle East, Indian subcontinent, and Southeast Asia³. However, due to
55 modernization, people from epidemic areas migrated to the non-epidemic area.
56 Hence, haemoglobin disorders have become a significant health problem in 71% of
57 229 countries globally⁵.

58

59 The recent report by the Malaysian Thalassemia Registry (MTR) has recorded a total
60 of 8681 thalassemia cases from 2007 until November 2018. Since the launch of the
61 National Thalassemia Preventive and Control Program in 2004, healthcare facilities
62 have been upgraded to provide better quality for patient management. Hence, the
63 survival rate of patients with thalassemia in Malaysia has improved⁶. With several
64 molecular studies have been done previously in the East and West Malaysia, genetic
65 heterogeneity is more observed in multiracial population in Malaysia with a diverse
66 spectrum of alpha (α -), beta (β -) and delta (δ -) globin genes mutations among the
67 patients with thalassemia syndromes⁷⁻¹¹. Beta-thalassemia is due to decreased beta-

68 globin chain synthesis of which, caused by a mutation in the *HBB* gene. The *HBB* gene
69 mapped on chromosome 11p15.4 with a region spanning from 5,225,464 to 5,229,395
70 bp on the reverse strand¹². Therefore, the identification of nucleic acid variations in the
71 *HBB* gene has improved our understanding of underlying causal mutations of beta-
72 thalassemia in Malaysia.

73

74 The clinical presentation and molecular circumstantial of beta-thalassemia are highly
75 heterogeneous and dependent on geographical and ethnicity factors¹³. The evidence
76 may be derived from genetic predisposition, which is unique to particular ethnic
77 groups, and that could enable targeted molecular analysis being designed [16, 17].
78 Genetic heterogeneity is more observed among different ethnicity in Malaysia with a
79 diverse spectrum of *HBB* gene mutations. According to Elizabeth & Ann (2010),
80 approximately 73% of Malay patients with beta-thalassemia were due to mutation at
81 codon 26(A>G) or HbE (β^E), IVS1-5(G>C) (severe β^+) and IVS1-1(G>T) (β^o). Whilst
82 for Malaysian Chinese, 90% of beta-thalassemia cases were due to codon 41/42 (-
83 TTCT) (β^o), IVS2-654(C>T), -28(A>G), codon 17(A>T) and codon 71/72(+A). In East
84 Malaysia, especially in Sabah, 90% of the Kadazan-Dusun with beta-thalassemia were
85 due to β -Filipino deletion (β^o)^{16,17}.

86

87 However, the genetic variant interaction in conferring the effect based on haplotype
88 inference has yet to be explored and refined in beta-thalassemia among the Malaysian
89 population. Deciphering the predisposing effect by the potential haplotype markers
90 can promote the exposition of underlying mechanisms of thalassemia development.
91 In this study, five single nucleotide polymorphisms (SNPs) within the *HBB* gene were
92 evaluated to determine its significance and haplotype structure inference with beta-

93 thalassemia in Malaysia, which was the first study conducted in Malaysia to the best
94 of our knowledge.

95

96 **2. RESULTS**

97

98 **Single association analysis**

99 In single-based association analysis, three tagging SNPs at IVS2-16G>C, IVS2-
100 666C>T and 3'UTR +314G>A showed a statistically significant association with beta-
101 thalassemia with p-value of 0.036, OR=1.300 [1.017~1.66]; 0.032, OR=0.765
102 [0.598~0.978] and 0.004, OR= 2.013 [1.238~3.272], respectively. However, tagging
103 SNP at IVS2-74T>G and 3'UTR +233G>C did not show statistically significant
104 association with beta-thalassemia of which, the p-value of 0.099 and 0.211. The minor
105 allele of these two variants showed a trend towards protective effect based on odds
106 ratios less than 1 (OR=0.794 [0.604~1.044] and OR=0.663 [0.347~1.267]
107 respectively). Table 1 depicts the genotypic association analysis of the five assigned
108 SNPs. The most common genotype for IVS2-74T>G, IVS2-16G>C, IVS2-666C>T,
109 3'UTR +233G>C and 3'UTR +314G>A was TT (59.8% in case and 52.6% in control
110 group), GC (49% in case and 49.1% in control group), CT (43% in case and 48.5% in
111 control group), GG (94.4% in case and 91.5% in control group) and GG (82.3% in case
112 and 90.4% in control group) respectively. Three tagging SNPs (IVS2-74T>G, 3'UTR
113 +233G>C and 3'UTR +314G>A) showed high homozygosity rate in case and control
114 groups. Meanwhile, a high heterozygosity rate was found in IVS2-16G>C and IVS2-
115 666C>T in both groups.

116

117

Table 1: Single association analysis of five tagging SNPs of the *HBB* gene with beta-thalassemia

SNP	Genotype data (frequency)			Case-control analysis		
	1/1	1/2	2/2	MAF	p-value	OR [95%CI]
IVS2-74T>G	149(0.598)	81(0.325)	19(0.076)	119(0.239)	0.099	0.794
	154(0.526)	112(0.382)	27(0.092)	166(0.283)		[0.604~1.044]
IVS2-16G>C	99(0.398)	122(0.490)	28(0.112)	178(0.357)	0.036	1.300
	98(0.334)	144(0.491)	51(0.174)	246(0.420)		[1.017~1.66]
IVS2-666C>T	106(0.426)	107(0.430)	36(0.145)	179(0.359)	0.032	0.765
	98(0.334)	142(0.485)	53(0.181)	248(0.423)		[0.598~0.978]
3'UTR +233G>C	237(0.944)	13(0.052)	1(0.004)	15(0.030)	0.211	0.663
	268(0.915)	24(0.082)	1(0.003)	26(0.044)		[0.347~1.267]
3'UTR +314G>A	205(0.823)	42(0.169)	2(0.008)	46(0.092)	0.004	2.013
	263(0.904)	28(0.096)	0(0.000)	28(0.048)		[1.238~3.272]

Case data is at the top line, while **control** data is at the bottom line. The **major** allele is depicted as 1. **Minor** allele is represented

as 2. MAF= Minor allele frequency. The p-value < 0.05 is considered significant in Pearson Chi-Square.

119 **Haplotype analysis**

120 Captivated by this favourable data in single association analysis, further investigation
121 was conducted using combined allele from IVS2-74T>G, IVS2-16G>C, IVS2-666C>T,
122 3'UTR +233G>C and 3'UTRt+314G>A of *HBB* gene in an attempt to evaluate the
123 predisposing effect of *HBB* intragenic haplotype with beta-thalassemia. The naming
124 system for the haplotype in this study is not related to the system used in the previous
125 PCR-RFLP based haplotyping studies. Haplotype analysis revealed significant
126 association for three haplotypes; 1-2-2-1-1, 1-2-1-1-1 and 1-1-1-1-1 with susceptibility
127 effect towards beta-thalassemia of which, the p-values were 6.49×10^{-7} (OR=10.371
128 [3.345~32.148]), 0.009 (OR=1.423 [1.095~1.850]) and 1.39×10^{-4} (OR=10.221
129 [2.345~44.555]) respectively. On the other hand, three haplotypes; 2-2-1-1-1, 1-1-2-
130 2-1 and 1-1-2-1-1 significantly conferred an opposing manner of effect to beta-
131 thalassemia with the p-value 0.006 (OR=0.668 [0.500~0.893]), 0.013 (OR=0.357
132 [0.153~0.830]) and 0.033 (OR=0.745 [0.567~0.977]) respectively. However, one
133 haplotype with allele combinations 1-1-2-1-2 did not show any significant association
134 with beta-thalassemia, where the p-value was 0.899, yet the trend was towards
135 susceptibility as depicted by OR=1.041 [0.559~1.939]). The summary of these findings
136 was tabulated in Table 2. Haplotype with the frequency <0.03 in both controls and
137 cases were automatically excluded from the analysis by the SHEsis online software.

138

139

140

Table 2: Haplotype analysis of IVS2-74T>G, IVS2-16G>C, IVS2-666C>T, 3'UTR +233G>C and 3'UTR +314G>A in all races dataset with 249 cases and 294 controls

**Haplotype	*Case (frequency)	*Control (frequency)	p-value	OR [95% CI]
2-2-1-1-1	95.08(0.192)	164.67(0.284)	0.006	0.668 [0.500~0.893]
1-2-2-1-1	26.38(0.053)	3.43(0.006)	6.49x10 ⁻⁷	10.371 [3.345~32.148]
1-2-1-1-1	167.60(0.338)	169.25(0.292)	0.009	1.423 [1.095~1.850]
1-1-2-2-1	7.08(0.014)	24.70(0.043)	0.013	0.357 [0.153~0.830]
1-1-2-1-2	18.79(0.038)	23.11(0.040)	0.899	1.041 [0.559~1.939]
1-1-2-1-1	120.08(0.242)	188.91(0.326)	0.033	0.745 [0.567~0.977]
1-1-1-1-1	15.61(0.031)	2.02(0.003)	1.39x10 ⁻⁴	10.221 [2.345~44.555]

*Frequency<0.03 in both controls and cases has been dropped in the analysis

****Major** allele is depicted as 1. **Minor** allele is depicted as 2. A sequential in allele combination represents for IVS2-74T>G, IVS2-16G>C, IVS2-666C>T, 3'UTR +233G>C and 3'UTR +314G>A respectively

141

142

143 **3. DISCUSSION**

144 In this study, we explored a single-based and haplotype association of five intragenic
145 *HBB* polymorphisms in beta-thalassemia cases from Malaysia. It was suggested that
146 the association of intragenic SNPs might be useful for the diagnosis and delineation
147 of the clinical heterogeneity of beta-thalassemia¹⁹. Furthermore, the intragenic SNPs
148 could be useful marker for linkage analysis and in prenatal diagnosis it can improve
149 the diagnostic errors of which, caused by recombination²⁰.

150

151 From the analysis of single-based association, two intronic polymorphisms; IVS2-
152 16G>C, and IVS2-666C>T, and one variant at 3' untranslated region to *HBB* gene
153 assigned as 3'UTR +314G>A were found significantly associated with beta-
154 thalassemia. The substitution of C to T allele at position 666 of intron 2 with minor
155 allele frequency (MAF) of 0.359 in case group and 0.423 in control group conferring
156 protection in beta-thalassemia with the odds ratio of 0.765 (p=0.032). However, we
157 noted that the MAF for IVS2-666C>T from this study was higher when compared with
158 global MAF in the ClinVar (0.286) database but lower compared to 1000 Genome
159 Project (0.713)²¹. The genotype distribution of this intronic polymorphism revealed the
160 heterozygote had yielded the highest frequency (48.5%) in the control group.
161 Association study done by Akhavan-Niaki et al. (2011) reported that IVS2-666C>T was
162 found to be linked to a mutation at codon 8(-AA) [HBB:c.25_26delAA], of which this
163 β° -mutation was mainly described among the population from the Middle East and the
164 Mediterranean. Hence, the authors suggested that IVS2-666C>T would be useful as
165 a marker for codon 8 genotyping in prenatal diagnosis²⁰.

166

167 Meanwhile, two other variants showed a significant susceptibility effect towards beta-
168 thalassemia: IVS2-16G>C and 3'UTR +314G>A. The MAF for IVS2-16G>C was 0.357
169 in the case group and 0.420 in the control group conferring susceptibility in beta-
170 thalassemia with the odds ratio of 1.300 ($p=0.036$). In comparison to global MAF from
171 the ClinVar database (0.280), MAF findings for IVS2-16G>C in this study were noted
172 higher but lower when compared to the 1000 Genomes Project (0.720) ²². The
173 untranslated region (UTR) is the sequence in the 3' region of a gene but not translated
174 during protein synthesis and contains regulatory element for the gene expression ²³.
175 A variant in the 3'UTR of the *HBB* gene, which is assigned as 3'UTR+314G>A was
176 found to have a significant susceptibility effect towards beta-thalassemia with the odds
177 ratio 2.013 ($p=0.004$). The MAFs were found to be 0.092 in the case group and 0.048
178 in the control group. However, we noted that there was very limited report of this
179 variant in the literature for further comparison. Overall, we noticed that the MAF for the
180 three significant variants in this study were still within the range of global MAF from
181 other studies reported in the ClinVar database [21, 22]. The different MAF value could
182 be varied across diverse ethnic or population as well as study sample size ²⁴.

183

184 In an attempt to further evaluate the role of *HBB* haplotypes in beta-thalassemia in
185 Malaysia, haplotype analysis revealed several susceptible and protective haplotypes
186 ²⁵. The potential applications of haplotype-tagged SNPs have been widely described
187 in the literature. Fields of application include, for example, disease association and
188 pharmacogenetic studies ²⁶. In this study, we identified seven different haplotypes
189 using the five intragenic *HBB* SNPs. A comparable finding was reported by Bilgen et
190 al (2011) for the haplotype analysis in the Turkish population. Likewise, the authors
191 have also reported that SNP based haplotyping using five intragenic SNPs has

192 successfully established the beta globin gene mutation related haplotypes ¹⁹. In the
193 earlier studies done by Fuchareon et al (2001) and Sanguansermri et al (2004) also
194 have reported association of certain haplotype pattern with HbE and common beta-
195 thalassemia mutation respectively by using PCR-RFLP method. To the best of our
196 knowledge, no study was done so far to evaluate the important role of intragenic *HBB*
197 SNPs in thalassemia syndrome in Southeast Asian region. In this study, we identified
198 six significant haplotypes of which, have important role for beta-thalassemia.
199 Noteworthy, individuals with haplotype that consists of all major alleles from our
200 assigned *HBB* polymorphisms (1-1-1-1-1) might have a higher risk in developing beta-
201 thalassemia. However, if the minor allele from IVS2-666C>T is substituted, the effect
202 becomes a protective effect. This allele transition might reveal the protective role from
203 the minor allele of IVS2-666C>T. The same effect is reflected in IVS2-16G>C.
204 However, the protective effect from the minor allele of IVS2-16G>C was not strong
205 enough to confer susceptibility for this haplotype.

206

207 Interesting to note that the combination of both minor alleles from IVS2-666C>T and
208 3'UTR +233G>C with other dominant alleles projected higher protection, which
209 elucidates the same protective role from 3'UTR +233G>C. These synergist effects
210 provide a better outcome for individuals with this haplotype 1-1-2-2-1. The same
211 synergist effect was also observed for haplotype 2-2-1-1-1, which revealed the
212 protective role from IVS2-74T>G and IVS2-16G>C. Likewise, the allele substitution for
213 3'UTR +314G>A in haplotype 1-1-2-1-2 dropped the protective effect from haplotype
214 1-1-2-1-1. The susceptible effect might explain this from a minor allele of 3'UTR
215 +314G>A. This haplotype-based association analysis was carried out to provide a
216 prediction of the predisposing effect and reveal the severity and possible prognosis

217 using haplotype-tagged SNPs of *HBB* gene for beta-thalassemia. Thus, this model
218 could be further developed for the improvement of clinical management of beta-
219 thalassemia in Malaysia mainly based on the personalized haplotype profile.

220

221 In conclusion, the presented study the first study on intragenic polymorphic markers
222 of the beta-globin gene involving the Malaysian population. Identification of
223 susceptible and protective haplotype markers that conferred the significant association
224 with beta-thalassemia in Malaysia can be further refined following the multi-ethnic
225 background of the Malaysian population. The association data on a single genotype
226 and haplotype might disclose the effect of *HBB* polymorphisms in beta-thalassemia
227 that might provide an impact in the understanding of beta-thalassemia propensity. This
228 study can be ascertained by larger sample size, and stratification by ethnicity should
229 be deliberated since Malaysia is inhabited by various ethnicity.

230

231 **MATERIALS & METHODS**

232

233 **Study population**

234 This cross-sectional study was conducted among the referral case for DNA analysis
235 of thalassemia syndromes in the Institute for Medical Research (IMR), Kuala Lumpur.
236 The study protocol was approved by the Medical Research Ethics Committee [MREC;
237 NMRR-18-3977-43849 (IIR)] and UniSZA Human Research Ethical Committee
238 [UniSZA/UHREC/2020/170]. Informed consent was obtained from each case prior
239 blood collection was done. Protocol of this study was in accordance with the
240 Declaration of Helsinki. A total of 543 (294 controls & 249 cases) archived cases from
241 the year 2011 until 2014 were reviewed for this study. Only cases with valid Malaysian

242 identity card numbers were included in this study. Cases with no sequencing results
243 and no valid Malaysian identity card numbers were excluded from this study. These
244 cases were molecularly ascertained via Sanger sequencing using 3730XL DNA
245 Analyser (Applied Biosystem, Foster City, CA, USA) for the presence of *HBB* gene
246 variation. Samples with heterozygous or compound heterozygous or homozygous
247 state of *HBB* gene mutations were grouped as cases. Whilst controls were the
248 samples without the known beta-globin gene mutation.

249

250 **SNP Genotyping**

251 Genomic DNA was extracted from peripheral blood using a commercial DNA
252 extraction kit (QIAGEN, Germany). The detection of the genotype for IVS2-74T>G
253 (HBB:c.315+74T>G), IVS2-16G>C (HBB:c.315+16G>C), IVS2-666C>T (HBB:c.316-
254 185C>T), 3'UTR +233G>C (HBB:c.*233G>C) and 3'UTR +314G>A (HBB:c.*314G>A)
255 polymorphic site in the *HBB* gene was performed using a direct DNA sequencing
256 technique in which the cycle sequencing used the BigDye® Terminator v3.1 cycle
257 sequencing kit. Sequence analysis was performed on CLC Main Workbench 6 version
258 6.6.1 software (CLC Bio, Denmark).

259

260 **Bioinformatics analysis**

261 The SHEsis Online software (<http://analysis.bio-x.cn/myAnalysis.php>) was employed
262 to assess the SNPs and haplotype association in which allelic and genotypic
263 distribution were compared between case and control groups¹⁸. The odds ratios (ORs)
264 value with a 95% confidence interval (95% CI) in which a p-value of 0.05 was
265 considered as significant.

266

267 **REFERENCES**

- 268 1. Old J. *Hemoglobinopathies and Thalassemias*. Academic Press; :1-44.
269 <https://www.sciencedirect.com/science/article/pii/B9780123838346000756?via>
270 %3Dihub. Accessed September 5, 2019.
- 271 2. Williams TN, Weatherall DJ. World distribution, population genetics, and health
272 burden of the hemoglobinopathies. *Cold Spring Harb Perspect Med*.
273 2012;2(9):a011692. doi:10.1101/cshperspect.a011692
- 274 3. Sanctis V De, Kattamis C, Canatan D, et al. β -thalassemia distribution in the old
275 world: An ancient disease seen from a historical standpoint. *Mediterr J Hematol*
276 *Infect Dis*. 2017. doi:10.4084/mjhid.2017.018
- 277 4. Greene DN, Vaughn CP, Crews BO, Agarwal AM. Advances in detection of
278 hemoglobinopathies. *Clin Chim Acta*. 2014. doi:10.1016/j.cca.2014.10.006
- 279 5. Modell B, Darlison M. *Global Epidemiology of Haemoglobin Disorders and*
280 *Derived Service Indicators*. Vol 86. World Health Organization; 2008:480-487.
281 doi:10.2471/BLT.06.036673
- 282 6. Mohd Ibrahim, H. Malaysian Thalassemia Registry Report 2018. 1st ed. Medical
283 Development Division, Ministry of Health M. *Malaysian Thalassaemia Registry*.
284 Vol 19.; 2019.
- 285 7. Tan J a M a, George E, Tan KL, et al. Molecular defects in the beta-globin gene
286 identified in different ethnic groups/populations during prenatal diagnosis for
287 beta-thalassemia: a Malaysian experience. *Clin Exp Med*. 2004;4(3):142-147.
288 doi:10.1007/s10238-004-0048-x
- 289 8. Rosline H, Ahmed SA, Al-Joudi FS, Rapiaah M, Naing NN, Adam NAM.
290 Thalassemia among blood donors at the Hospital Universiti Sains Malaysia.
291 *Southeast Asian J Trop Med Public Health*. 2006;37(3):549-552.

- 322 <http://www.ncbi.nlm.nih.gov/pubmed/17120978>. Accessed August 22, 2019.
- 323 9. Tan JAMAA, Chin SS, Ong GB, et al. Transfusion-dependent Thalassemia in
324 northern Sarawak: A molecular study to identify different genotypes in the multi-
325 ethnic groups and the importance of genomic sequencing in unstudied
326 populations. *Public Health Genomics*. 2015;18(1). doi:10.1159/000368342
- 327 10. Teh LK, George E, Lai MI, Tan JAMA, Wong L, Ismail P. Molecular basis of
328 transfusion dependent beta-thalassemia major patients in Sabah. *J Hum Genet*.
329 2014;59(3):119-123. doi:10.1038/jhg.2013.131
- 330 11. Mohd Yatim NF, Abd. Rahim M, Menon K, et al. Molecular characterization of
331 α - and β -thalassaemia among Malay patients. *Int J Mol Sci*. 2014.
332 doi:10.3390/ijms15058835
- 333 12. HBB Gene - GeneCards | HBB Protein | HBB Antibody.
334 <https://www.genecards.org/cgi-bin/carddisp.pl?gene=HBB>. Accessed June 8,
335 2020.
- 336 13. Taghavifar F, Hamid M, Shariati G. Gene expression in blood from an individual
337 with β -thalassemia: An RNA sequence analysis. *Mol Genet Genomic Med*.
338 2019;7(7):e740. doi:10.1002/mgg3.740
- 339 14. Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of
340 thalassemia. *Int J Lab Hematol*. 2016;38. doi:10.1111/ijlh.12527
- 341 15. Taib WRW, Ahmad N, Ali E, Muda TFMT, Jusoh NM, Rebutan HMA. Suggestive
342 evidence of protective haplotype within TGF-B1 gene region in breast density
343 utilizing fine mapping analysis. *Meta Gene*. 2020.
344 doi:10.1016/j.mgene.2019.100631
- 345 16. Tan J-AMAAMA, Lee P-CC, Wee Y-CC, et al. High prevalence of alpha- and
346 beta-thalassemia in the kadazandusuns in east Malaysia: Challenges in

- 317 providing effective health care for an indigenous group. *J Biomed Biotechnol.*
318 2010;2010. doi:10.1155/2010/706872
- 319 17. Elizabeth G, Ann MTJA. Genotype-phenotype diversity of beta-thalassemia in
320 Malaysia: Treatment options and emerging therapies. *Med J Malaysia.* 2010.
- 321 18. Yong Y, He L, Shi Yy, He L. SHEsis, a powerful software platform for analyses
322 of linkage disequilibrium, haplotype construction, and genetic association at
323 polymorphism loci. *Cell Res.* 2005;15:97. <https://doi.org/10.1038/sj.cr.7310101>.
- 324 19. Bilgen T, Arikan Y, Canatan D, Yeşilipek A, Keser I. The association between
325 intragenic SNP haplotypes and mutations of the beta globin gene in a Turkish
326 population. *Blood Cells, Mol Dis.* 2011. doi:10.1016/j.bcmed.2011.01.004
- 327 20. Akhavan-Niaki H, Seresti SS, Asghari B, Banihashemi A. IVSII-666 of human
328 beta-globin gene: A polymorphic marker linked to codon 8(-AA) mutation. *Genet*
329 *Test Mol Biomarkers.* 2011. doi:10.1089/gtmb.2010.0242
- 330 21. National Center for Biotechnology Information. VCV000036316.3 - ClinVar -
331 NCBI. https://www.ncbi.nlm.nih.gov/clinvar/variation/36316/#id_first. Accessed
332 June 14, 2020.
- 333 22. National Center for Biotechnology Information. VCV000256345.3 - ClinVar -
334 NCBI. <https://www.ncbi.nlm.nih.gov/clinvar/variation/256345/>. Accessed June
335 11, 2020.
- 336 23. Barrett LW, Fletcher S, Wilton SD. Untranslated Gene Regions and Other Non-
337 coding Elements. In: ; 2013. doi:10.1007/978-3-0348-0679-4_1
- 338 24. Shamsuddin AA, Ahmad A, Wan Taib WR. Haplotype analysis of leptin gene
339 polymorphisms in obesity among Malays in Terengganu, Malaysia population.
340 *Med J Malaysia.* 2018.
- 341 25. Wan Taib WR. Study of Association of TGF-β1 Polymorphism with Breast

342 Density in a Tertiary Medical Center of Malaysia. *Med Health*. 2017.

343 doi:10.17576/mh.2017.1202.15

344 26. Ouyang C, Krontiris TG. Identification and functional significance of SNPs

345 underlying conserved haplotype frameworks across ethnic populations.

346 *Pharmacogenet Genomics*. 2006. doi:10.1097/01.fpc.0000220569.82842.9b

347

348 **ACKNOWLEDGEMENTS**

349 The authors would like to thank IMR and MTR for their cooperation and participation

350 in this study. We also would like to thank the Director General of Health, Malaysia, for

351 his permission to publish this article.

352

353 **AUTHOR CONTRIBUTIONS**

354 N.A. and W.W.T. wrote the main manuscript text. N.A., N.K., and W.W.T. run the

355 investigation, revised the manuscript for important intellectual content. N.A, N.K.,

356 W.W.T., H.A.N.A., W.N.W.A.J., E.E. and H.I. contributed to all aspects of the

357 investigation, including methodological design, data collection and analysis,

358 interpretation of the results. All authors reviewed and revised the manuscript.

359

360 **DECLARATION OF INTEREST**

361 The authors report no conflict of interest. The authors alone are responsible for the

362 content and writing of this article.

363

364 **END OF THIS ARTICLE**